Apple Hits Record as Gilead and Rio Tinto Announce Major Moves
Apple reached an all-time high during a busy day of Q3 earnings releases. Gilead agreed to acquire an oral IL-23R inhibitor for $1.28 billion, and Rio Tinto committed $1.9 billion to a bauxite project in Australia. Other actions included Zai Lab’s $250 million private placement and Rivian’s acquisition of Third Dimension AI.
Gilead’s definitive deal for an oral IL-23R inhibitor is valued at $1.28 billion and adds immunology work to a company historically associated with antivirals. Rio Tinto’s $1.9 billion commitment covers the Kangwinan bauxite project in Western Cape, Queensland, supporting its longer-term aluminum supply planning.
Other transactions included Zai Lab’s $250 million private placement, Rivian’s undisclosed purchase of Third Dimension AI for autonomous-driving technology, Exchange Income’s completed $30 million TerraPro acquisition, and Lindsay’s agreement for Brazilian hose-reel maker Setorial Irrigação. Melar shareholders approved its combination with Everli, while Black Hills and NorthWestern Energy disclosed the merged utility’s name.
The Gilead deal could eventually affect patients if the immunology asset advances, while Rio Tinto’s bauxite investment may influence local employment, infrastructure, and environmental scrutiny in Queensland. Rivian’s autonomous-tech purchase could shape future vehicle safety and driver expectations, and Zai Lab’s financing may affect drug-development timelines for patients in its markets. Buybacks and dividends may mainly affect investors and capital allocation, with indirect effects on employees and communities.